Gemcitabine has a strong broad-spectrum antitumor activity and a unique mechanism of action and is widely used in the treatment of malignant tumors in clinical practice; oxaliplatin has the advantage of significant effects and few adverse effects; and apatinib is able to antagonize vascular endothelial growth factor receptor 2 (VEGFR-2) and can effectively promote apoptosis of tumor cells. This evidence concerns the gene KDR and cancer.